Vanguard Capital Management
LCTX icon

Vanguard Capital Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Vanguard Capital Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.9M Buy
9,054,918
+736,233
+9% +$1.02M ﹤0.01% 2717
2026
Q1 		$13.1M Buy
+8,318,685
New +$14M ﹤0.01% 2577

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Capital Management's LCTX Position: Q2 2026 in Review

Vanguard Capital Management increased its Lineage Cell Therapeutics (LCTX) stake by 8.9% in Q2 2026, buying an estimated $1.02M and bringing the position to 9,054,918 shares worth $11.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2717.

Vanguard Capital Management first reported a position in LCTX in Q1 2026 and has held it in 2 quarters since. The position peaked at $13.1M in Q1 2026. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Vanguard Capital Management held 9,054,918 shares of Lineage Cell Therapeutics worth $11.9M as of Q2 2026.
  • Vanguard Capital Management bought 736,233 Lineage Cell Therapeutics shares in Q2 2026, an estimated $1.02M.
  • Lineage Cell Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2717 holding.
  • Vanguard Capital Management first reported a position in Lineage Cell Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Lineage Cell Therapeutics position peaked at $13.1M in Q1 2026.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.